Apogee Therapeutics, Inc. APGE
At closeSep 2, 2026, 4:00 PM EDT
After hours · Sep 2, 4:00 PM ET
- YTD
- +78.95%
- 1 year
- +208.31%
- Market cap
- 10.22B
- EPS (ttm)
- -4.34
- Shares out
- 62.20M
- Forward P/E
- -26.00
- YTD return
- +78.95%
- 1-year return
- +208.31%
- Avg volume
- 2.95M
- Open
- 135.06
- Previous close
- 135.07
- Day's range
- 135.06 – 135.09
- 52-week range
- 35.39 – 135.09
- Beta
- 0.33
- Analysts
- Hold
- Price target
- 134.62 (-0.3%)
- Earnings date
- Nov 9, 2026
Key statistics
- Enterprise value
- 9.22B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 8.49
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -145.62M
- Total cash
- 971.93M
- Total debt
- 6.83M
- Return on equity
- -32.46%
- Short % of float
- 7.28%
- 50-day average
- 134.18
- 200-day average
- 93.12
Analyst view
Consensus: hold
- Target (low)
- 133.00
- Target (mean)
- 134.62
- Target (high)
- 135.11
- Strong buy0
- Buy1
- Hold6
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -1.25.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -1.14 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -1.07 | -1.14 | -0.07 | -6.54% |
| May 11, 2026 | Mar 31, 2026 | -1.07 | -1.06 | +0.01 | +0.93% |
| Mar 2, 2026 | Dec 31, 2025 | -1.05 | -1.03 | +0.02 | +1.90% |
| Nov 10, 2025 | Sep 30, 2025 | -1.12 | -1.11 | +0.01 | +0.89% |
| Aug 11, 2025 | Jun 30, 2025 | -1.03 | -1.13 | -0.10 | -9.71% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 2026 | Truist Securities | main | Hold | Hold |
| Aug 12, 2026 | BTIG | down | Buy | Neutral |
| Jun 24, 2026 | Stifel | down | Buy | Hold |
| Jun 24, 2026 | TD Cowen | down | Buy | Hold |
| Jun 24, 2026 | Guggenheim | down | Buy | Neutral |
| Jun 24, 2026 | Mizuho | down | Outperform | Neutral |
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- apogeetherapeutics.com
News
4 Elite Dividend Stocks That Pay You Passive Income Every Quarter 
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday 
Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9 Billion, Camp Mystic Bankruptcy 
Okta To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Wednesday 
This Principal Financial Group Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday 
This IBM Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday 
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday 
This Zions Bancorp Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday 
12 Health Care Stocks Moving In Monday's Intraday Session 
Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday
Your note
Sign in to keep a note on APGE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DAMBKOWSKI CARL | Officer | Sale | Aug 4, 2026 | 168,498 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 6, 2026 | 0 |
| HENDERSON JANE | Chief Financial Officer | Stock Gift | Jul 23, 2026 | 158,371 |
| HENDERSON MICHAEL THOMAS | Chief Executive Officer | Stock Gift | Jul 9, 2026 | 920,941 |
| MCKENNA MARK C | Director | Purchase | Dec 11, 2024 | 20,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Venrock Adviser, LLC | 13.65% | 8,493,321 | 1.15B | Jun 29, 2026 |
| Blackrock Inc. | 8.85% | 5,507,032 | 743.83M | Jun 29, 2026 |
| HBK Investments L P | 4.58% | 2,850,000 | 384.95M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.14% | 2,572,119 | 347.42M | Jun 29, 2026 |
| FMR, LLC | 4.01% | 2,493,137 | 336.75M | Jun 29, 2026 |
| State Street Corporation | 3.69% | 2,297,743 | 310.36M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 1,870,667 | 252.67M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.40% | 1,490,737 | 201.35M | Apr 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.94% | 1,203,674 | 162.58M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.86% | 1,157,561 | 156.35M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.08% | 673,950 | 91.03M | Jun 29, 2026 |
| T. Rowe Price Exch-Trd Fd.s, Inc.-T Rowe Price Capital Appreciation Eq | 1.05% | 653,461 | 88.26M | Jun 29, 2026 |